Skip to main content
. 2018 May 30;8:8383. doi: 10.1038/s41598-018-26560-9

Figure 3.

Figure 3

Binding of anti-CLDN-5 ECR mAbs to CLDN–expressing cells. HT-1080 cells expressing CLDNs were treated with vehicle (PBS) or 5 µg/mL of anti-CLDN-5 ECR mAbs. After fluorescein-labeled secondary antibody treatment, cells were analyzed by flow cytometry.